# Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

> **NCT02803138** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 256 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Ombitasvir/paritaprevir/ritonavir
- **DRUG:** Dasabuvir
- **DRUG:** Ribavirin
- **BEHAVIORAL:** Patient support program

## Key facts

- **NCT ID:** NCT02803138
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-07
- **Primary completion:** 2018-10-21
- **Final completion:** 2018-10-21
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2019-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02803138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02803138, "Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02803138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*